Cardinal Health (CAH)
229.51
+1.05 (0.46%)
NYSE· Last Trade: Aug 23rd, 4:15 PM EDT
Detailed Quote
| Previous Close | 228.46 |
|---|---|
| Open | 228.80 |
| Bid | 226.70 |
| Ask | 230.00 |
| Day's Range | 228.16 - 231.29 |
| 52 Week Range | 145.87 - 258.30 |
| Volume | 1,386,836 |
| Market Cap | 66.66B |
| PE Ratio (TTM) | 34.62 |
| EPS (TTM) | 6.6 |
| Dividend & Yield | 2.064 (0.90%) |
| 1 Month Average Volume | 1,977,345 |
Chart
About Cardinal Health (CAH)
Cardinal Health is a global healthcare services and products company that plays a vital role in the medical supply chain. It specializes in the distribution of pharmaceuticals and medical supplies to healthcare institutions, pharmacies, and patients. In addition to its distribution services, the company also manufactures and provides a wide range of medical and surgical products, including surgical gloves, apparel, and other healthcare-related items. Cardinal Health is committed to enhancing patient care by ensuring the availability of essential products and services, while also striving to improve the efficiency and effectiveness of healthcare delivery across various settings. Read More
News & Press Releases
Mary C. Scherer reduced her direct equity but retains 2,811 shares after the stock delivered a 58% return over the past year.
Via The Motley Fool · August 23, 2026
Alt divested part of his direct equity stake after the stock surged 57% over the past year, retaining 20,495 shares worth $4.82 million.
Via The Motley Fool · August 23, 2026
This insider sale cut an equity stake following a strong 57% one-year stock run, leaving $4.2 million in direct holdings.
Via The Motley Fool · August 23, 2026
Weitzman's equity reduction follows a 57% one-year stock price surge, leaving her with $18.3 million in direct holdings.
Via The Motley Fool · August 23, 2026
Michelle Greene reduced her direct equity stake following strong stock appreciation, retaining 10,330 shares worth $2.43 million.
Via The Motley Fool · August 23, 2026
Jessica Mayer holds 33,076 shares valued at $7.77 million.
Via The Motley Fool · August 23, 2026
Hollar divested 125,000 shares across two trading sessions, reducing his direct holdings following a 58% one-year stock surge.
Via The Motley Fool · August 23, 2026
GLP-1 tailwinds and specialty strength drove pharma profit up 21% in Q4.
Via The Motley Fool · August 18, 2026
Cardinal Health’s second quarter results reflected strong profit growth, despite revenue falling short of Wall Street’s expectations. Management credited bro...
Via StockStory · August 18, 2026
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability. But not all ...
Via StockStory · August 13, 2026
Cardinal Health stock hit a new all-time high after mixed earnings, with analyst price target hikes, gene therapy logistics wins and a 29-year dividend growth streak supporting the uptrend.
Via MarketBeat · August 12, 2026
Healthcare distributor and services company Cardinal Health (NYSE:CAH) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 5.8% year...
Via StockStory · August 12, 2026
Cardinal Health (NYSE:CAH) reported fourth-quarter fiscal 2026 results marked by growth in revenue, operating earnings and adjusted earnings per share, supported by demand in its pharmaceutical and specialty businesses and a one-time tariff-related benefit in its medical products segment.
For the q
Via MarketBeat · August 11, 2026
US stocks mixed, Dow up 150 points. Industrials gain 1%, communication services fall 1.1%. Cardinal Health (NYSE: CAH) up 8%. Oil up 0.4%, gold up 0.6%.
Via Benzinga · August 11, 2026
Healthcare distributor and services company Cardinal Health (NYSE:CAH) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 5.8% year...
Via StockStory · August 11, 2026
Healthcare distributor and services company Cardinal Health (NYSE:CAH) will be announcing earnings results this Tuesday before market hours. Here’s what to e...
Via StockStory · August 9, 2026
McKesson posted strong fiscal 2026 results, raised guidance, boosted buybacks and its dividend, and maintains a Moderate Buy rating from analysts amid its evolving specialty business mix.
Via MarketBeat · July 31, 2026
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorab...
Via StockStory · July 31, 2026
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Those leading the charge have not only reali...
Via StockStory · July 28, 2026
When Wall Street turns bearish on a stock, it’s worth paying attention. These calls stand out because analysts rarely issue grim ratings on companies for fea...
Via StockStory · July 22, 2026
Large-cap stocks are known for their staying power and ability to weather market storms better than smaller competitors. However, their sheer size makes it m...
Via StockStory · June 26, 2026
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand. Not...
Via StockStory · June 18, 2026
The best-performing stocks typically have robust sales growth, increasing margins, and rising returns on capital, and those that can maintain this trifecta y...
Via StockStory · June 2, 2026
The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...
Via StockStory · May 27, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...
Via StockStory · May 22, 2026